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ABSTRACT
Background & Aims: Liver fibrogenesis – scarring of the liver that can lead to 
cirrhosis and liver cancer – is characterized by hepatocyte impairment, capillarization 
of liver sinusoidal endothelial cells (LSECs) and hepatic stellate cell (HSC) activation. 
To date, the molecular determinants of a healthy human liver cell phenotype remain 
largely uncharacterized. Here, we assess the transcriptome and the genome-wide 
promoter methylome specific for purified, non-cultured human hepatocytes, LSECs and 
HSCs, and investigate the nature of epigenetic changes accompanying transcriptional 
changes associated with activation of HSCs.
Material and methods: Gene expression profile and promoter methylome of purified, 
uncultured human liver cells and culture-activated HSCs were respectively determined 
using Affymetrix HG-U219 genechips and by methylated DNA immunoprecipitation 
coupled to promoter array hybridization. Histone modification patterns were assessed 
at the single-gene level by chromatin immunoprecipitation and quantitative PCR.
Results: We unveil a DNA-methylation-based epigenetic relationship between 
hepatocytes, LSECs and HSCs despite their distinct ontogeny. We show that liver 
cell type-specific DNA methylation targets early developmental and differentiation-
associated functions. Integrative analysis of promoter methylome and transcriptome 
reveals partial concordance between DNA methylation and transcriptional changes 
associated with human HSC activation. Further, we identify concordant histone 
methylation and acetylation changes in the promoter and putative novel enhancer 
elements of genes involved in liver fibrosis.
Conclusions: Our study provides the first epigenetic blueprint of three distinct 




The liver is a complex organ with strong adaptive 
and regenerative capacity. However, persistent injury 
of any etiology can lead to liver fibrosis and cirrhosis, 
conditions associated with high morbidity and mortality 
[1]. Over 80% of hepatocellular carcinoma (HCC) cases 
have cirrhosis and most of the remainder have moderate 
to advanced fibrosis, making it the primary risk factors 
for the development of HCC [2]. These pathologies are 
characterized by impairment of hepatocyte (HEP) function 
[3], liver sinusoidal endothelial cell (LSEC) capillarization 
[4] and activation of hepatic stellate cells (HSCs) and 
Kupffer cells (KCs) [5, 6]. Under physiological conditions, 
these cell types form a collaborative sinusoidal unit that 
ensures functional organ integrity. Accordingly, there is 
evidence that the different liver cell types maintain each 
other’s differentiated phenotype [7–10].
Using cell fate tracing techniques, activated HSCs 
(aHSCs) have unequivocally been identified as the 
major source of excessive fibrillar extracellular matrix 
(ECM) in the fibrotic liver [5]. This is independent of the 
underlying disease etiology, making HSCs the primary 
target for anti-fibrotic therapies across all types of liver 
disease. Identifying the molecular determinants defining 
the phenotype of the various healthy human liver cell 
types is an essential foundation for the recognition of 
disease-associated changes. Moreover, despite extensive 
studies of the process of HSC activation in recent years, a 
comprehensive characterization of human primary HSCs 
is still lacking. In particular, changes in gene expression 
and the molecular events underlying these changes remain 
largely uncharacterized.
Gene expression is regulated by a complex interplay 
between transcription factors, chromatin remodeling 
processes and epigenetic modifications of DNA and 
histones, the core components of chromatin. DNA 
methylation consists in the addition of a methyl group 
on the 5 position of a cytosine within CpG dinucleotides. 
DNA methylation is reversible; it contributes to the proper 
regulation of gene expression and gene silencing in normal 
cells and is often associated with long-term developmental 
gene silencing [11, 12]. Increasing evidence links altered 
DNA methylation to tissue fibrosis [13]. Widespread DNA 
methylation changes have been reported in fibrotic lung 
tissue, in experimental liver fibrosis and in advanced non-
alcoholic fatty liver disease [14–17]. Involvement of DNA 
methylation in HSC activation has also been shown [16]. 
Indeed, maintenance DNA methyltransferase DNMT1 
and methyl-binding protein MeCP2 have been shown to 
play a role in promoting the activated phenotype of HSCs 
by repressing genes critical in the maintenance of HSC 
quiescence [16, 18–20]. However, the extent to which 
the DNA methylome of HSCs is altered during HSC 
activation, and how these potential alterations correlate 
with changes in gene expression, remain unclear.
Post-translational modifications of histones (hPTMs) 
also regulate tissue- and cell type-specific gene expression 
patterns [21], and deregulated expression of factors 
regulating these modifications often lead to disease [22]. 
Histone modifications notably include methylation and 
acetylation of lysines (K) on histone H3. Trimethylation 
of H3K27 (H3K27me3) elicits the formation of 
transcriptionally repressive chromatin. In contrast, H3K27 
acetylation (ac) loosens histone-DNA interactions, favoring 
gene expression [22]. While both H3K27me3 and H3K27ac 
can reciprocally mark promoters, H3K27ac is also found 
on active enhancers. Enhancer elements are also marked 
by H3K4me1 irrespective of activity, while H3K4me3 
marks the transcription start site (TSS) of active and 
many inactive genes [23]. Combinational associations of 
DNA methylation and histone modifications are read by 
effector proteins to modulate gene expression, providing 
cell type and tissue identity. There is however currently 
no information on the nature of histone modifications 
associated with genes involved in human HSC activation.
In this study, we report the first comprehensive and 
integrative analysis of the transcriptome and genome-wide 
promoter DNA methylome that underpin the differentiated 
phenotype of HEPs, LSECs and quiescent (q)HSCs 
purified from healthy human liver tissue. We also provide 
the transcriptome, promoter DNA methylome and locus-
specific changes in histone modifications upon in vitro 
activation of human primary HSCs. Our data unveil an 
epigenetic relationship between the different hepatic cell 
types despite their distinct ontogeny. They also provide the 
epigenetic blueprint of quiescent and activated HSCs and 
identify novel putative enhancer elements for key genes 
involved in liver fibrosis.
RESULTS
Cell type-specific gene expression patterns of 
uncultured human primary HEPs, LSECs and 
HSCs
Using a two-step collagenase perfusion tech nique 
[24] and fluorescence-activated cell sorting, we isolated 
HEPs, HSCs and LSECs from healthy cadaveric liver 
tissue and immediately processed each cell type for gene 
expression and promoter DNA methylation profiling 
(Supplementary Figure S1A–S1B). Cell purity was 
evaluated by differential expression of distinct liver cell 
type marker genes, including CYP3A4, HNF4A (HEP) 
[25, 26], PDGFRB, VIM (HSCs) [27–29], CD32b and 
LYVE1 (LSEC) [30–32] (Supplementary Figure S1C). 
Microarray gene expression analysis reveals that 80% 
of all genes (n = 16565/20816) analyzed have similar 
expression levels (P > 0.05, ANOVA) in HSCs, LSECs and 
HEPs, while 20% are significantly differentially expressed 
in at least one of the three cell types (Supplementary 
Figure S1D). To identify cell type-specific genes, we 
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focused on genes with a ≥ 2-fold higher expression level 
in one cell type relative to the two others. This reveals 923, 
54 and 72 annotated genes selectively expressed in HEPs, 
HSCs and LSECs respectively (Figure 1A; Supplementary 
Table S1). Gene Ontology (GO) terms associated with 
these sets of genes confirm their specialized roles in 
metabolic processes [33], ECM homeostasis [34] and 
endocytosis [35], respectively (Figure 1B; Supplementary 
Table S2). This analysis enabled the identification of 
many genes with a specific expression pattern in the 3 
liver cell types examined, including genes encoding for 
new potential cell specific surface markers (Figure 1C; 
Supplementary Table S1) [7–10, 36–38].
Promoter DNA methylation marks distinct gene 
sets in HEPs, HSCs and LSECs
The unexpected overall similarity of gene 
expression patterns detected in purified, non-cultured 
HEPs, HSCs and LSECs suggests an “intrinsic” identity 
of these cell types despite their distinct function. Gene 
expression patterns are largely determined by reversible 
epigenetic modifications. Thus, we assessed the epigenetic 
relationship between uncultured HEPs, HSCs and LSECs 
by methylated DNA immunoprecipitation coupled to 
promoter array hybridization (MeDIP-chip). We examined 
methylation profiles through 4 kilobases (kb) of genome 
across all human RefSeq promoters, spanning −3 to +1 kb 
relative to the transcription start site (TSS). Correlations 
of MeDIP/Input log2 ratios show high reproducibility 
between technical replicates (r > 0.95; data not shown). 
Pair-wise comparisons of MaxTen values of DNA 
methylation intensities for all promoters (see Methods; 
Figure 2A) and browser views of promoter methylation 
profiles show overlap but also differences between cell 
types (Figure 2B).
Combining MeDiP-chip data from two donors for 
each cell type (Supplementary Figure S2A), we identify 
with high confidence (KS test, P ≤ 0.01) a total of 
7526 genes with a methylated promoter in HEPs, 5862 
in HSCs and 7281 in LSECs, representing 30–35% 
of all RefSeq promoters (Figure 2C; Supplementary 
Figure S2A, intersects; Supplementary Table S3). 
We also identify a “core” of 4339 methylated genes, 
illustrating similarity in the promoter methylomes of 
these three cell types (Figure 2C). GO enrichment 
analysis shows that this gene core mainly pertains to 
early developmental and reproduction/gametogenesis-
associated functions (Figure 2D), consistent with 
long-term repressive DNA methylation of reproduction-
associated genes in the soma [39, 40]. Interestingly, 
~600 to ~1200 genes emerge as uniquely methylated 
in either cell type (Figure 2C); these are linked to 
functions pertaining to chromatin assembly and gene 
regulation (HEP), RNA metabolism and signalling 
(HSC) and intracellular transport and lipid metabolism 
(LSEC) (Figure 2D; Supplementary Table S4). We 
conclude that 60 to nearly 75% of methylated genes are 
shared between HEPs, HSCs and LSECs, while 10–16% 
are uniquely methylated in either cell type (Figure 2E; 
Supplementary Table S5). Thus, while these cell types 
share a common promoter methylation pattern, they are 
also characterized by some epigenetic diversity.
We next evaluated the extent to which the 
promoter methylome of HSCs, LSECs and HEPs was 
similar to that of an unrelated, also uncultured, cell type, 
such as bone marrow-derived CD34+ hematopoietic 
progenitors, which we have previously analyzed by 
MeDIP-chip [40]. We find that 42–47% of promoters 
methylated in CD34+ cells are also methylated in HSCs, 
LSECs or HEPs (Figure 2F). Thus, at a promoter DNA 
methylome level, bone marrow CD34+ cells show a 
similar ‘epigenetic distance’ to any of the three liver 
cell types examined. Moreover, promoters methylated 
in HSCs, LSECs and HEPs as a whole compared to 
CD34+ cells are mainly involved in cell cycle regulation 
(data not shown). These results suggest that, despite 
functional and ontology differences between HSCs, 
LSECs, HEPs and CD34+ hematopoietic progenitors, 
the ‘epigenetic distance’ between the three liver cell 
types is shorter than between any of these cell types 
and CD34+ cells.
Human HSC activation is associated with a 
profound change in gene expression and DNA 
methylation
We next determined changes in transcriptome and 
promoter DNA methylome associated with human HSC 
activation. To this end, we compared freshly isolated, 
uncultured qHSCs with culture-activated HSCs (aHSCs). 
We find that over 2000 genes are differentially expressed 
upon HSC activation, representing ~10% of the total genes 
examined and consisting primarily of down-regulated 
(6.1%) and fewer up-regulated (3.6%) genes, with the 
latter ones being mainly linked to the ECM (Figure 3A–3C, 
Supplementary Table S6). This profiling allowed the 
confirmation of genes previously known to be associated 
with HSC activation, such as GREM1 [41], LOX [42] and 
TNC [43]. Importantly, this also enabled identification of 
novel putative human in vitro HSC activation-associated 
genes (Figure 3D, Supplementary Table S6). Surprisingly, 
we find limited overlap (~12–18%) between the global 
changes in gene expression underlying in vitro activation 
of mouse primary HSCs – by far the most common 
model used to study HSC biology – and human primary 
HSCs (Figure 3E), suggesting a different transcriptional 
cascade underpinning HSC activation in both species. As 
illustrative example, neurotrimin (NTM), a well-known 
quiescence associated gene in mouse HSCs [44], was 
found to be strongly upregulated during human HSC 
activation (Figure 3F).
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Further, we examined changes in the promoter 
methylome of aHSCs and find that it deviates substantially 
from that of qHSCs. MeDIP-chip reveals 5862 methylated 
genes in qHSCs and 5191 in aHSCs (Figure 4A). We 
identify a core overlap of only 2760 methylated genes 
(Figure 4A), i.e. ~50% of all methylated genes in either 
qHSCs or aHSCs. We note a net reduction in promoter 
methylation in aHSCs, with demethylation of 3102 
promoters (53% of all methylated promoters before culture; 
Figure, 4A), including several different members of the 
collagen and lysyl oxidase gene families (Figure 4B), the 
main constituents and enzymatic stabilizers of fibrotic scar 
tissue [45]. De novo methylation of 2431 promoters was 
observed, representing 47% of all methylated promoters 
in aHSCs (Figure 4A). Demethylated genes in aHSCs are 
notably involved in regulation of nucleotide metabolism 
Figure 1: Gene expression profiling of HSCs, LSECs and HEPs identifies liver cell type selective gene expression 
patterns. A. Heatmap of relative expression levels of genes classified based on expression patterns in HEPs, HSCs and LSECs. Cell type 
classification is based on a ≥ 2-fold higher expression compared to both other cell types. B. Most significant GO terms for each gene set 
shown in (A). C. Normalized expression level of novel indicated HEP, HSC or LSEC-specific genes.
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Figure 2: MeDIP-chip analysis of the promoter DNA-methylome of human HEPs, HSCs and LSECs. A. Two-dimensional 
scatter plots of MaxTen values of methylation intensities for all promoters in HEPs, HSCs and LSECs. Genes with a promoter significantly 
methylated in one cell type are colored; non-significantly methylated genes are shown in gray. B. Browser view of promoter methylation on 
all chromosomes; right, zoom-in of GFRA3 methylation in HEPs, HSCs and LSECs (log (MeDIP/Input) ratios). Red and blue colors point to 
methylation peaks and depletions, respectively. C. Venn diagram analysis of numbers of genes with a methylated promoter in HSCs, LSECs 
and HEPs. D. Most significant GO terms for the methylation ‘core’ and for cell type-specific methylated genes. E. Proportion of genes that are 
uniquely or commonly methylated between two or more cell types. F. Promoter methylation in HSCs, LSECs and HEPs relative to CD34+ bone 
marrow progenitors. Percentage of methylated genes in cell types shown on the x-axis that are also methylated in cell types shown on the y-axis.
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pertaining to cell cycle progression and signal transduction, 
consistent with induction of cell division upon activation 
and adjustments in signal transduction pathways as a result 
of changing conditions.
Recent work has shown that developmental 
transitions can be associated with differential methylation 
of promoter regions upstream of the TSS rather than at 
or downstream of the TSS [46]. We find that in qHSCs, 
Figure 3: The gene expression changes elicited by in vitro HSC activation poorly correlate between mouse and 
human. A. Heatmap of relative expression levels of genes classified based on differential expression (≥ 2-fold) between human qHSCs and 
culture induced aHSCs. B. Venn diagram analysis of numbers of genes (absolute and as percentage of total analyzed genes) shown in (A). 
C. Enriched GO terms for genes differentially expressed between qHSCs and aHSCs. D. Normalized, relative expression levels of the top 
20 most-upregulated genes following human HSC activation in vitro. E. Venn diagram analysis illustrating the overlap of annotated genes 
differentially regulated following in vitro activation of human and mouse HSCs. Mouse data from [59]. F. Relative neurotrimin (NTM) 
mRNA expression levels in freshly isolated, non-cultured qHSCs and culture aHSCs from human and mouse.
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Figure 4: Culture-induced HSC activation reprograms promoter DNA methylation. A. Venn diagram analysis of the number 
of genes with a methylated promoter in qHSCs and aHSCs. B. Browser views of promoter methylation profiles (log (MeDIP/Input) ratios) 
for indicated genes in qHSCs and aHSCs. Red and blue colors point to methylation peaks and depletions, respectively. C. Heatmap of 
genes up-regulated and hypo-methylated after HSC activation. D. Boxwhisker plot of ACTG2 expression in qHSCs and aHSCs. E. Bisulfite 
sequencing analysis of CpG methylation in the ACTG2 promoter in qHSCs and aHSCs. Four CpGs are examined (columns) in 5 sequenced 
clones (rows). ● methylated CpG; ○ unmethylated CpG. F. Heatmap of genes down-regulated and hyper-methylated after HSC activation. 
G. Boxwhisker plot of APOB expression in qHSCs and aHSCs. H. Bisulfite sequencing analysis of CpG methylation in the APOB promoter 
in qHSCs and aHSCs. Five CpGs were analyzed.
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methylation is equally distributed into upstream, 
downstream or at the TSS (‘TSS methylation’), with 
~30% of promoters showing upstream methylation (only). 
In aHSCs however, upstream methylation significantly 
increased to 51–58% for the same two donors (L4 and 
L11), primarily at the expense of ‘TSS methylation’ 
(P < 0.001, Chi-Square test) (Supplementary Figure S2C). 
Upstream methylation is also prominent in aHSCs from 
two other donors (L8, L10), suggesting that this might be 
a common feature of HSC culture.
We find 416 genes (Supplementary Table S7) 
with concordant changes in DNA methylation and 
gene expression upon HSC activation. For these genes, 
transcriptional upregulation in aHSCs correlates with 
abrogation or reduction in promoter methylation, as 
shown for several pro-fibrogenic genes such as ACTG2, 
LOXL1, LOXL2 and COL4A1/2 (Figure 4B–4E). 
Conversely, transcriptional downregulation among these 
416 genes is associated with DNA hypermethylation (e.g. 
APOB, ADAMTS9, MMP15 and CXCL9; Figure 4F–4H). 
Independent bisulfite sequencing analysis of ACTG2 
and APOB, two genes strongly differentially expressed 
between human qHSCs and aHSCs, corroborates their 
differential methylation status detected by MeDIP-chip 
(Figure 4E, 4H).
To evaluate the physiological relevance of these 
findings, we determined whether similar DNA methylation 
changes would also occur in mice HSCs after a 4-week 
induction of fibrogenesis with carbon tetrachloride (CCl4) 
(Supplementary Figure S3A–S3C). Bisulfite sequencing 
analysis of Loxl1, Loxl2, Col4a1 and Col4a2, which 
are strongly upregulated in in vivo activated human 
and mouse HSCs (Supplementary Figure S4A–S4B), 
shows no difference in promoter methylation between 
qHSCs and aHSCs (Supplementary Figure S3D). This 
is explained by the already unmethylated state of these 
genes in qHSCs isolated from control untreated mice 
(Supplementary Figure S3D) and suggests, rather, that 
methylation of at least a subset of pro-fibrogenic genes 
is distinct between mice and humans. Our transcriptome 
and methylome data collectively indicate that a significant 
gene set is differentially expressed with concordant DNA 
methylation changes upon in vitro activation of human 
qHSCs. Moreover, the difference in methylation state of 
specific genes between quiescent mouse and human HSCs 
argues for the importance of using human HSCs in vitro 
as a model system to elucidate the molecular regulation of 
pro-fibrotic gene activation in humans.
HSC activation is linked to alterations in histone 
methylation on quiescence-associated and  
pro-fibrotic genes
The non-straightforward relationship between 
promoter DNA methylation and changes in gene 
expression following HSC activation prompted the query 
of additional chromatin marks that would account for 
differential gene expression. We examined by chromatin 
immunoprecipitation (ChIP)-qPCR the profiles of 
H3K4me1, H3K4me3, H3K27ac and H3K27me3 [47] 
on upstream regulatory regions of a set of pro-fibrogenic 
genes (Figure 5, Supplementary Table S8). First, we 
find that promoters of all genes examined are marked 
by H3K4me3, albeit at various levels, in either qHSCs, 
aHSCs, or both (Figure 5A, 5B), consistent with a marking 
of the TSS for transcription. The level of H3K4me3 
enrichment at these sites reflects the expression level of 
the gene in most cases (e.g. ACTG2 (increase), COL1A2 
(elevated) and COL3A1 (elevated), APOB and NOTCH1 
(decreased) but not always (e.g. COL1A1, LOX, LOXL1, 
LOXL2) (Figure 5A, 5B). Because ChIP data represent 
an average of all cells in a population, this could reflect 
biological variation in the HSC culture. We find that the 
promoters of COL1A1, COL1A2, COL3A1, COL4A1 
and ACTG2 are enriched in H3K27ac, coinciding with 
increased expression in aHSCs (see also [48]) (Figure 5A). 
In contrast, the quiescence genes APOB and NOTCH1 
show reduced H3K4me3 and/or H3K27ac after HSC 
activation, in line with transcriptional down-regulation in 
aHSCs (Figure 5B). Interestingly, we also note that the 
LOX, LOXL1 and COL1A2 promoters in aHSCs display 
reduced H3K27me3 in aHSCs, strongly suggesting a 
depression mechanism coinciding with transcriptional 
up-regulation. These results collectively indicate that 
gene expression changes occurring after culture-induced 
HSC activation are linked to, for the most part (albeit not 
always), concording changes in modifications of H3K4 
and H3K27 on promoters.
Identification of novel putative enhancer 
elements in pro-fibrotic genes
To gain further insight into histone modifications 
which may affect activation-induced transcriptional 
changes, we examined, for a subset of genes showing 
discordant promoter H3 methylation and expression 
changes (notably COL4A1, LOXL1, LOXL2), additional 
putative regulatory elements. We searched for putative 
enhancers for a subset of these genes, given that some 
enhancers cluster near genes they regulate [49]. To this 
end, we examined published ChIP-sequencing profiles 
for H3K4me1, an enhancer mark, and H3K27ac, which 
together with H3K4me1 characterizes active enhancers. 
The ChIP-seq profiles examined were previously obtained 
during adipogenic differentiation of primary human 
adipocyte progenitors [50], and were used with the rationale 
that HSC activation can be defined as a ‘differentiation’ 
from a quiescent, adipogenic-like state (qHSCs) into a 
fibrogenic myofibroblast-like state (aHSCs). Thus, in vitro 
HSC activation arguably displays (anti)parallels to in vitro 
adipogenesis, and anti-adipogenic regulation has been 
shown to underlie HSC activation [51].
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Figure 5: Histone H3 methylation and acetylation occupancy on promoters of aHSC- and qHSC-associated 
genes. ChIP analysis of DNA isolated from freshly isolated human qHSCs and cultured induced aHSCs. A. qHSC associated genes. 
B. aHSC associated genes. The main graphs show the percentage enrichment of H3K4me1, H3K4me3, H3K27me3 and H3K27ac 
relative to input, in human qHSCs and aHSCs. The right insert panels show the fold increase or decrease in mRNA levels for the 
respective gene during human HSC activation in vitro.
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Examination of chromatin marks of pro-fibrogenic 
genes in pre-adipocytes identifies upstream, downstream 
and intragenic sites at the LOXL1, LOXL2 and COL4A1 
loci marked by high H3K4me1 and low H3K4me3 
co-marked (or not) by H3K27ac, which together with 
H3K4me1 marks active enhancers (data not shown; see 
Figure 6A for sites examined). Interestingly, the results 
obtained by performing ChiPs for these sites in qHSCs 
and aHSCs clearly show that H3K4me1 is enriched at 
all sites examined after HSC activation (Figure 6B); 
these gains in H3K4me1 strongly suggest that (putative) 
enhancer elements are being ‘marked’ for transcriptional 
activation upon HSC activation. Additionally, for each 
gene, we identify an increase in H3K27ac, reflecting the 
use (activity) of the putative enhancer. This is particularly 
evident for a downstream site within the COL4A1 gene 
immediately upstream of exon 3, a region upstream of 
exon 2 in the LOXL1 gene, and an upstream region nearly 
7 kilobases upstream of the LOXL2 TSS (Figure 6B). 
Importantly, these findings point to the localization of 
functional enhancer elements hitherto unidentified in key 
pro-fibrotic genes up-regulated upon HSC activation.
DISCUSSION
We report the first comparative transcriptome and 
promoter DNA methylation of freshly isolated uncultured 
human HEPs, HSCs and LSECs. We show that in vitro 
activation of HSCs is associated with changes in DNA 
methylation and histone modification on thousands of 
promoters including some that drive pro-fibrotic gene 
expression.
Cell type-specific gene sets identified by 
transcriptomic analysis of HEPs, HSCs and LSECs confirm 
their specialized roles in metabolic processes [33], ECM 
homeostasis [34] and endocytosis [35]. For example, we find 
that HSCs express SOD3, the major superoxide dismutase 
known to bind and protect vascular endothelial cells from 
oxygen radicals [36]. In line with a previous study identifying 
vascular smooth muscle cells as major source of SOD3 
in the arterial wall [37], our finding suggests a potential 
role for HSCs in protecting the liver-specific vasculature 
by suppression of various pathological processes. On the 
other hand, LSECs express GMFG, a glia maturation factor 
which negatively regulates lipopolysaccharide-induced 
TLR4 signaling in macrophages [38], suggesting a role for 
LSECs in the maintenance of Kupffer cell (KC) and HSC 
quiescence. These observations, in line with previous studies 
in rodent cells [7–10], suggest that liver cells promote the 
maintenance of each other’s phenotype.
Cell type-specific methylation is associated with 
processes disabled in the course of hepatic specification 
and development. Methylated genes in HSCs are enriched 
in RNA metabolism consistent with the quiescence of 
HSCs in healthy liver, a state associated with low RNA 
metabolic activity [52]. Genes methylated in LSECs are 
linked to lipid metabolism confirming that LSECs are the 
only cell type among those examined which do not have 
a lipid storage or processing role, unlike HSCs and HEPs 
[53–55]. In accordance with a developmentally repressive 
role of DNA methylation, these functions are likely to be 
repressed by DNA methylation in LSECs, epigenetically 
segregating them from HSCs and HEPs. Methylated genes 
in HEPs pertain almost exclusively to chromatin assembly 
functions. This may be related to extensive nuclear and 
chromatin remodeling taking place during hepatocyte 
development and maturation, often leading to binucleated 
cells and a substantial degree of multiploidy [56]. The 
methylated state of chromatin remodeling-associated 
genes suggests that these nuclear remodeling activities 
have become repressed by DNA methylation once 
hepatocyte maturation has occurred. Thus in the post-natal 
liver, promoter methylation targets early developmental 
functions disabled during liver organogenesis.
At the transcriptome and methylome level, LSECs 
and HSCs are more similar to each other than to HEPs. 
Nonetheless, HEPs, HSCs and LSECs seem to display 
a shorter ‘epigenetic distance’ between each other 
than to bone marrow-derived freshly isolated CD34+ 
hematopoietic progenitors [40], an unrelated cell type. 
A common ontogenic environment during liver 
development is likely to impact this epigenetic relationship 
[57]. This is in line with the similar transcriptome of 
hepatic and pancreatic stellate cells, which are thought 
to share a common origin [58]. This suggests that 
developmental origin is an important determinant of the 
hepatic transcriptome and methylome.
Our study demonstrates that human HSC activation 
is associated with extensive remodeling of the promoter 
methylation landscape. The link between promoter DNA 
methylation and gene expression is nonetheless rather 
promiscuous, consistent with the non-straightforward 
relationship between promoter methylation and expression 
status of the associated gene [39, 40]. Our study constitutes, 
to our knowledge, the first reference of transcriptome and 
methylome changes elicited by culture-induced activation 
of human HSCs. To what extent these profiles reflect 
fibrosis-induced HSC activation in humans [44] remains to 
be determined, however this is challenged by the current 
difficulty to isolate pure activated HSCs from fibrotic livers. 
Indeed, it is not until recently that ultra-pure HSC isolation 
procedures from fibrotic mouse livers have been published 
as a validated method to determine gene expression changes 
during HSC activation, devoid of cell culture artifacts [59, 
60]. To the best of our knowledge, there is to date only one 
report about the isolation of aHSCs from cirrhotic human 
livers [61]. Of note, in the latter study both the quiescent 
and in vivo activated HSCs were in vitro cultured.
Recently, another DNA modification at the 
5′ position of cytosine, i.e. 5-hydroxymethylcytosine 
(5 hmC) was discovered [62, 63]. This novel cytosine 
modification occurs through the oxidation of 5mC by 
Oncotarget26739www.impactjournals.com/oncotarget
Figure 6: Identification of putative novel enhancer elements for the pro-fibrotic COL4A1, LOXL1 and LOXL2 
genes. A. Schematic representation of putative poised or active enhancers upstream or downstream of the COL4A1, LOXL1 and LOXL2 
TSS. Two intragenic poised putative enhancer regions were identified 69 kb and 90 kb downstream of the COL4A1 TSS. Intragenic active 
and downstream poised putative enhancers were identified 14 kb and 39 kb downstream of the LOXL1 TSS respectively, and an upstream 
active putative enhancer was identified 6.5 kb upstream of LOXL2 TSS. B. Graphs showing the percentage enrichment of H3K4me1 and 
H3K27ac relative to input, in human qHSCs and aHSCs, at the sites shown in (A) IR, DR, UR; Intragenic, downstream, upstream region.
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the TET (Ten-Eleven-Translocation) family of enzymes 
and is believed to be a key intermediate of active DNA 
demethylation [64]. A limitation of the MeDIP-Chip 
and bisulfite sequencing approaches is that they do not 
allow for the discrimination of DNA methylation and 
hydroxymethylation. While the genomic distribution of 
DNA hydroxymethylation is well studied in different 
tissues and cell types, its role and functional significance 
across the genome are still unclear. While evidence 
suggests that like methylation, the concentration of 
hydroxymethylated cytosines at promoter regions 
negatively correlates with transcriptional activity [65], 
other studies have associated 5 hmC with increased 
transcriptional levels [66–68]. As increasing evidence 
suggest that both DNA modifications may have different 
functional outcomes, future studies to decipher the 
dynamics of DNA hydroxymethylation during HSC 
activation will provide novel insights into the role of 
this epigenetic modification in setting a pro-fibrogenic 
transcription program.
We find that around 10% of the analyzed genes are 
deregulated upon activation, with a majority of genes 
being down-regulated, and provide a list of previously 
known and unknown genes with a differential expression 
between human qHSCs and aHSCs. Although in vitro 
activation is currently the most common model of HSC 
activation, it incompletely replicates gene expression 
changes associated with in vivo activation, as shown in 
rodents [44, 59]. We show here that in vitro activation of 
human and mouse HSCs induces a different transcriptional 
response, emphasizing the importance of validating 
observations made with mouse or rat HSC cultures for 
relevance in human primary cells or tissue.
Importantly, our findings highlight the identification 
of novel putative and functional enhancer elements 
for pro-fibrotic genes, which epigenetically respond to 
culture-induced HSC activation by displaying marks of 
regulatory activity, namely H3K4me1 in combination 
with H3K27ac. This is clearly evidenced for LOXL1, 
LOXL2 and COL4A1. Of note, these genes show histone 
modification changes on promoters that do not concord 
with their transcriptional activation. This suggests that 
their transcriptional activity is modulated by enhancer 
marking (and hence ‘activity’) rather than promoter 
marking per se. It is tempting to speculate that these 
putatively novel enhancers may play a key role in the 
maintenance of a pro-fibrogenic gene expression program.
MATERIALS AND METHODS
Patients
Gene expression and DNA methylation profiling was 
performed using HEPs, HSCs and LSECs isolated from 
cadaveric donors (Table 1). HEPs were also harvested 
from consenting patients undergoing hepatic resections 
for liver metastasis from colorectal carcinoma (CRC). 
The protocol and conducted experiments were approved 
by the ethical committees of St-Luc Hospital and faculty 
of Medicine of Université Catholique de Louvain, and by 
the Norwegian Research Ethics Committee. An agreement 
from the Belgian Ministry of Health was obtained for the 
hepatocyte and hepatic stem cell bank.
Human liver cell isolations
Human liver cells were isolated from the left liver 
segment of healthy donors up to 12 hours after clamping 
using a two-step perfusion technique [24]. Livers were 
kept on ice until sequential perfusion with an EGTA and 
digestion enzyme solution (0.9 mg/ml collagenase P and 
0.03 mg/ml soybean trypsin inhibitor) was performed. 
Hepatocytes (HEPs) were separated from the non-
parenchymal liver cells by low-speed (50 g) centrifugation 
steps followed by two washing steps and purified by means 
of a Percoll gradient. Dissociated single non-parenchymal 
cells were suspended in a 5% FBS, 2 mM EDTA phosphate 
buffered saline (PBS) (106cells/100μL) and incubated for 
30 min at 4°C with 500 ng/106 cells anti-CD32 (Abcam, 
Cambridge, United Kingdom) and 1 μg/106 cells anti-CD45 
(BD Biosciences, San Jose, CA) or corresponding isotype 
controls. Cells were washed twice by centrifugation and 
Table 1: Clinical characteristics of the liver cell donors
Donor number Health status Age Gender Ischemia time
L4 Healthy 12 years Female 16 h 30
L8 Healthy 1 day Male 4 h 40
L10 Healthy 7 months Female 5 h 20
L11 Healthy 7 days Male 4 h 25
F2 Trauma 17 years Male 9 h
F23 Trauma 16 years Female <10 h
B6T Colorectal cancer 67 years Female <1 h
B5O Colorectal cancer 75 years Male <1 h
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resuspended in 2 mM EDTA PBS, before FACS sorting. 
Enriched populations of human qHSCs were sorted through 
a negative selection for CD32 (Ex: 488 nm; Em: 575 nm) 
and CD45 (Ex: 495 nm; Em: 519 nm) expressing cells and 
a positive selection for ultraviolet positivity (retinyl esters 
are auto-fluorescent at 328 nm), using a FACS-Aria (BD 
Biosciences). Enriched populations of LSECs were obtained 
as CD32+CD45- cells (Supplementary Figure S1A–S1B) 
and 7-aminoactinomycin (eBioscience, San Diego, CA) 
was used to discriminate viable from non-viable cells. On 
average, 15–20 × 106 HEPs were isolated from 1 g of liver 
tissue and 7.3% (±7.5) HSCs and 4% (±2.1) LSECs were 
sorted from the total number of non-parenchymal cells. 
Separated populations of HEPs, qHSCs and LSECs were 
immediately used for total cell RNA for gene expression 
profiling or DNA extraction for DNA methylation profiling 
and chromatin immunoprecipitation (ChIP).
In vitro activation of human primary HSCs
Homogeneous populations of aHSCs were obtained 
as described previously [69]. In brief, the qHSC-enriched 
population obtained after Nycodenz (Nyegaard, Oslo, 
Norway) gradient centrifugation were plated on plastic 
culture dishes (Greiner Bio-one, Monroe, NC) and allowed 
to activate and expand for up to 3 to 4 passages in DMEM 
(Lonza, Verviers, Belgium) supplemented with 10% fetal 
bovine serum (Biochrom GmbH, Germany) at 37°C in a 
humidified atmosphere with 5% CO2. Purified qHSC and 
in vitro aHSC populations were immediately used for total 
DNA extraction and bisulfite sequencing.




Murine qHSC and in vivo aHSC populations were 
isolated from male BALB/c mice (Charles River Laboratories, 
L’Arbresle, France) (aged 12 weeks) as described [70] with 
some modifications. Briefly, after enzymatic perfusion of the 
liver and low-speed centrifugation steps to remove HEPs, 
HSCs were purified from the non-parenchymal cell mixture 
through FACS-sorting for UV-positive cells using a FACS-
Aria. For in vivo activation of HSCs, mice underwent eight 
intraperitoneal injections over 4 weeks of 50 μl CCl4/100 g 
body weight in mineral oil (Sigma-Aldrich, St. Louis, MO). 
All procedures on animals were carried out in accordance 
with University’s guidelines for the care and use of laboratory 
animals in research and the performed experiments were 
approved by the ethical committee of the Vrije Universiteit 
Brussel in project 13-212-3.
Gene expression profiling
Total RNA was isolated by using RNeasy 
MICROKit (Qiagen GmbH, Hilden, Germany) 
following manufacturer’s recommendations. Total RNA 
concentration and quality control was assessed using RNA 
6000 pico kit (Agilent, Santa Clara, CA, USA). Due to 
the small amount of RNA obtained, RNA samples were 
amplified by using Ovation PicoSL System V2 (NuGene 
Technologies, CA, USA) and ENCORe Biotin module 
(NuGene technologies). RNA MinElute Reaction Cleanup 
Kit (Qiagen) was used to purify amplified RNA. RNA 
samples were labeled and hybridized by using GeneChip 
Hybridization Control Kit and GeneChip Hybridization, 
Wash and stain Kit HT (Affymetrix, Santa Clara, CA, 
USA), respectively. Labeled RNA samples were then 
hybridized to Affymetrix HG-U219 genechips (16 arrays 
plate) (Affymetrix) according to the manufacturer’s 
instructions. Data normalization and analysis was 
performed using GeneSpring GX12 (Agilent, Santa 
Clara, CA) as described previously [71]. For detection of 
differentially expressed genes, a P-value cut-off of 0.05 
was used in combination with a fold-change cut-off of 2.0. 
Raw data are made publically available on the NCBI Gene 
Expression Omnibus database, with accession number 
GSE68000.
RNA purification and RTq-PCR
Total cell RNA was extracted and purified using the 
Reliaprep RNA cell Miniprep System (Promega, Madison, 
WI) and converted to cDNA by reverse transcription using 
the Revert Aid Kit (ThermoFisher Scientific, St. Leon-Rot, 
Germany). Quantitative real-time polymerase chain 
reaction was performed using the GoTaq qPCR Master 
Mix with BRYTE green (Promega). A 7500 real time PCR 
system was used and data was analyzed using System SDS 
software v2.0.6 (Applied Biosystems).
Bisulfite genomic sequencing
DNA was purified and bisulfite-converted using 
the EpiTect Bisulfite Kit (Qiagen). Converted DNA 
was amplified by PCR using primers designed using 
Methprimer (http://www.urogene.org/methprimer/) 
(Supplementary Table S8). The TSS position was 
determined using Ensembl (http://www.ensembl.org). 
PCR conditions were 95°C for 5 min and 35 cycles 
of 95°C 1 min, 58°C 2 min, 72°C 2 min, followed 
by 10 min at 72°C. PCR products were purified from 
an agarose gel with the GenElute Gel Extraction Kit 
(Sigma) and cloned into E. coli by TOPO TA cloning 
(Life Technologies) and sequenced. Methylation data 
are shown as methylated CpG (filled) and unmethylated 
CpG (empty) circles.
Methyl-DNA immunoprecipitation and data 
analysis
MeDIP was performed and data were analyzed as 
described [40, 72]. In short, genomic DNA was purified 
and fragmented by sonication in a BioruptorTM (Diagenode) 
to obtain DNA fragments of 200–500 bp. Methylated 
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fragments (3 μg) were immunoprecipitated using 5 μg anti-
5-methylcytosine antibodies (Diagenode, MAb-006.100). 
MeDIP and input DNA were amplified by 14 PCR cycles 
using the WGA2 kit (Sigma-Aldrich) and cleaned up 
(MinElute PCR Purification Kit; Qiagen). Input and MeDIP 
DNA were labeled with Cy3 and Cy5, respectively, and 
hybridized onto Roche-Nimblegen HG18 RefSeq Promoter 
arrays (No. C4226–00-01). Data analysis was done as 
described [40] using a one-sided Kolmogorov-Smirnov 
(KS) windowed test to identify probes with a significantly 
positive signal. Resulting score for each probe was the P-
value from the windowed test around that probe. Using 
NimbleScan, methylated peak data were generated from P-
values by querying for ≥ 2 probes with P ≤ 0.01.
For comparison of promoter DNA methylation 
between each liver cell type and bone marrow CD34+ 
cells, we focused on one donor for each liver cell type 
since methylation data from one CD34+ cell donor were 
originally collected [40]. Moreover, analysis was restricted 
to the genomic window originally examined, i.e. from −2.2 
to +0.5 kb relative to TSS in order to match our earlier 
dataset for CD34+ cells (see Supplementary Figure S2B).
MeDIP data viewing and access
MeDIP data were viewed using the Integrated 
Genomics Viewer (IGV) and deposited under NCBI GEO 
GSE66796.
Chromatin immunoprecipitation (ChIP)
DNA and protein were cross-linked with 1% 
formaldehyde, cells lysed, chromatin fragmented by 
sonication under cooling for 4 × 8 min (30 sec ON/OFF) on 
“High” in a BioruptorTM (Diagenode) to obtain chromatin 
fragments of 200–500 bp. After sedimentation, chromatin 
fractions from four donors were pooled. Dynabeads® 
Protein A (Life Technologies) in RIPA buffer were mixed 
with 2.5 μg antibody (Diagenode: H3K4me3 pAb-003–
050, H3K27me3 pAb-069–050, H3K27ac pAb-174–050 
or H3K4me1 pAb-037–050) and incubated overnight at 
4°C. Chromatin was diluted 1:4 in RIPA containing 1X 
protease inhibitor cocktail, 1 mM PMSF and 20 mM 
sodium butyrate. Approximately 35 A260 units of chromatin 
in 100 μl was used per ChIP and incubated with antibody-
bead complexes for 2 h at 4°C. Immunoprecipitated 
material was RNase-treated with 33 ng/μl 
RNase (Roche) in elution buffer, digested with Proteinase 
K and isolated by phenol-chloroform-isoamylalcohol 
extraction. ChIP DNA was dissolved in 10 μl Milli-Q 
water. All ChIP DNA and 1/10 of input DNA was 
amplified by 25 cycles using the WGA4 kit (Sigma-
Aldrich). Amplified ChIP DNA was purified with the 
QIAquick PCR Purification Kit (Qiagen) and eluted with 
30 μl elution buffer (1/10 dilution in Milli-Q water). In 
order to analyze many promoters by quantitative (q)
PCR, amplified ChIP material (2 μl of 1/100 dilution) 
was re-amplified and purified as above. We show that the 
reamplification of ChIP DNA before qPCR maintains the 
enrichment profiles of histone modifications tested (and 
RNA Pol II) on the models genes examined, i.e. MYOG 
and GAPDH (Supplementary Figure S5). Re-amplified 
ChIP DNA was analyzed by qPCR using IQ SYBR® Green 
(BioRad) with ChIP primers listed in Supplementary Table 
S8. PCR conditions were 95°C for 3 min and 40 cycles of 
95°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec.
Statistical analysis
GraphPad Prism v4.0.0 (GraphPad Software, La 
Jolla, CA) and GeneSpring GX12 (Agilent) were used for 
statistical analysis. Differences among groups were tested 
for statistical significance by One-way ANOVA with 
posthoc Tukey analysis or Student’s t-test. Differences 
were considered statistically significant when P values 
were < 0.05.
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